2 completed, 1 unknown. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow Beijing Protgen Biotechnology Development Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites Recombinant Human Serum Albumin, Human Serum Albumin - Cirrhotic Ascites | Phase 2 / Phase 3 | Completed | Beijing Protgen Biotechnology Development Co., Ltd. | 390 | 2024-08-19 | 2026-03-10 |
| Phase II/III of Recombinant Human Serum Albumin Recombinant Human Serum Albumin, Human serum albumin - Cirrhotic Ascites | Phase 2 / Phase 3 | Completed | Beijing Protgen Biotechnology Development Co., Ltd. | 92 | 2023-05-24 | 2026-03-10 |
| Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer pegylated endostatin and Paclitaxel-Carboplatin, Placebo and Paclitaxel-Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Unknown | Beijing Protgen Biotechnology Development Co., Ltd. | 300 | 2011-05-01 | 2012-02-07 |
Carcinoma, Non-Small-Cell Lung (1)
Serum Albumin, Human (2) · recombinant human serum albumin-heme (2) · CP protocol (1)
China (3)
Jidong Jia, Ph.D (2) · Yan Sun, MD (1)